Bristol Myers Squibb have extended their research collaboration aimed at designing and optimizing small-molecule drugs for ...

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing d | Dianthus and Boehringer Ingelheim ...

Academic scientists and pharmaceutical companies alike are embracing artificial intelligence, even as questions linger about ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AI has advanced molecule design, yet synthetic feasibility remains a bottleneck. Chemistry-first approaches offer a practical ...

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Computational drug discovery and design integrates advanced computer‐aided methodologies with chemical and biological insights to accelerate the identification and optimisation of therapeutic agents.

Breast and Gynecologic Cancer Care for Sexual Minority Women and Transgender People The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly ...